In conclusion, our results demonstrated that the targeted complement inhibitor CRIg/FH may hold great potential for MG treatment, in which the therapeutic effect results not only from the direct complement inhibition but also from the modulation of adaptive immune responses. The gene discussed is FH; the disease is myasthenia gravis.